Menu Back toLS50: Transformation and Innovation in Drug Development with Environmental Changes Induced by COVID-19

18th DIA Japan Annual Meeting 2021

All prices are exclusive of 10% Japanese consumption tax

LS50: Transformation and Innovation in Drug Development with Environmental Changes Induced by COVID-19

Session Chair(s)

Marie  Shiga

Marie Shiga

  • Manager, Health Industries Advisory
  • PwC Consulting LLC, Japan

Speaker(s)

Michiyo  Ohshima, MBA

Michiyo Ohshima, MBA

  • Senior Director, Head of Japan Portfolio and Project Management
  • Japan
Noboru  Yamamoto, MD, PhD

Noboru Yamamoto, MD, PhD

  • Deputy Director, Department of Experimental Therapeutics
  • National Cancer Center Hospital, Japan
Minori  Niso

Minori Niso

  • Associate Brand Marketing Director, APAC Marketing
  • PAREXEL International Inc., Japan

Contact us